Clinical trials: Blepharospasm
Bilateral Blepharospasm (BEB)
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
This phase 3 study will serve to collect efficacy and safety data of two different doses of NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve.
- Trial name
- NCT01896895
- Testing
- IncobulinumtoxinA (Xeomin), 25 Units, IncobotulinumtoxinA (Xeomin), 12.5 Units, IncobotulinumtoxinA (Xeomin), 35 Units
- Where
- 11 sites in Greece, Malaysia and 1 more
- Volunteers
- 61 people
- Sponsor
- Merz Pharmaceuticals GmbH
Dystonia
Deep Brain Stimulation in Patients With Dystonia
The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation (DBS) of the subthalamic nucleus (STN)for primary dystonia.
- Trial name
- STN DBS (NCT00773604)
- Testing
- Medtronic implantable deep brain stimulation (DBS) system
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Francisco
Blepharospasm
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA…
- Trial name
- NCT00406367
- Testing
- incobotulinumtoxinA (Xeomin)
- Where
- 2 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Merz Pharmaceuticals GmbH
Focal Dystonia
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
Background: Blepharospasm is caused by excessive contraction of the muscles that close the eye. It can be treated with injections of botulinum neurotoxin (BoNT), which works by weakening those muscles.
- Trial name
- NCT00942851
- Testing
- Acetyl-Hexapeptide Topical Treatment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Benign Essential Blepharospasm
rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients.
- Trial name
- NCT02370875
- Testing
- Magstim RapidStim2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Blepharospasm
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm.
- Trial name
- NCT00761592
- Testing
- Botulinum Toxin Type A 900kDa, Botulinum Toxin Type A 150kDa
- Where
- 3 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Allergan
Cervical Dystonia, Blepharospasm
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical…
- Trial name
- NCT01814774
- Testing
- No Intervention
- Where
- 2 sites in Norway, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Allergan
Tears; Excess, Eyelid Spasm
Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure
The purpose of this research study is to test if Topical (applied to the surface of the eye) Botulinum Toxin temporarily lowers the upper eyelid and makes the eyelid appear less open and thereby affects the eye surface and…
- Trial name
- NCT06080438
- Testing
- Botulinum toxin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Focal Dystonia
Acetyl Hexapeptide-8 for Blepharospasm
Background: Blepharospasm is caused by excessive contraction of the muscles that close the eye. One treatment is botulinum neurotoxin (BoNT), which works by weakening those muscles.
- Trial name
- NCT01750346
- Testing
- Topical acetyl hexapeptide-8
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Blepharospasm, Torticollis
MDs on Botox Utility (MOBILITY)
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
- Conditions
- Blepharospasm, Torticollis, Strabismus, Muscle Spasticity
- Trial name
- NCT00535938
- Testing
- botulinum toxin type A
- Where
- Canada
- Volunteers
- 1,372 people
- Sponsor
- Allergan